Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Vifor Pharma (VIFN.S)

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (CHF) Price Target (CHF) Rating
2019-03-27132.15114.00Sell
2019-04-29135.30120.00Sell
2020-04-16140.70150.00Neutral
2020-07-03144.45149.00Neutral
2020-08-12131.65142.00Neutral
2020-10-20119.60129.00Neutral
2021-01-22125.05118.00Sell
2021-03-01116.75116.00Neutral
2021-03-05116.95119.00Neutral
2021-03-29128.70127.00Neutral
2021-12-17159.70167.00Neutral
2022-05-16179.00179.00Neutral

Disclosures

  • UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
  • Within the past 12 months, UBS Securities LLC and/or its affiliates have received compensation for products and services other than investment banking services from this company/entity.
  • UBS Group AG, its affiliates or subsidiaries beneficially owned 1% or more of a class of this company`s common equity securities as of last month`s end (or the prior month`s end if this report is dated less than 10 days after the most recent month`s end).
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day.